Telaprevir-induced DRESS

J Drugs Dermatol. 2014 Feb;13(2):199-200.

Abstract

Telaprevir, a protease inhibitor, was recently approved for management of Chronic Hepatits C (CHC) due to HCV genotype 1. Various RCTs have demonstarted increased incidence of cutaneous adverse effects with use of Telaprevir. Herein, we report two cases of drug rash with eosinophilia and systemic symptoms (DRESS) secondary to Telaprevir use.

Publication types

  • Case Reports

MeSH terms

  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use
  • Drug Hypersensitivity Syndrome / etiology*
  • Genotype
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / drug therapy
  • Hepatitis C, Chronic / virology
  • Humans
  • Male
  • Middle Aged
  • Oligopeptides / adverse effects*
  • Oligopeptides / therapeutic use
  • Protease Inhibitors / adverse effects*
  • Protease Inhibitors / therapeutic use

Substances

  • Antiviral Agents
  • Oligopeptides
  • Protease Inhibitors
  • telaprevir